Status:
UNKNOWN
Cholestatic Drug-induced Liver Injury
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Hepatitis, Toxic
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Cholestatic drug-induced liver injury (DILI) is the severe form of DILI with a grave outcome. Drug-metabolizing enzymes play an important role in the metabolism of drugs. The genetic polymorphism of d...
Detailed Description
Cholestatic drug-induced liver injury (DILI) is the severe form of DILI with a grave outcome. Drug-metabolizing enzymes play an important role in the metabolism of drugs. The genetic polymorphism of d...
Eligibility Criteria
Inclusion
- Drug-induced liver injury, meet the DILIN criteria.
Exclusion
- Other systemic diseases may cause elevation of liver enzymes: viral hepatitis, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, hemochromatosis, congestive heart failure, hypoxia, sepsis.
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT01141322
Start Date
August 1 2007
End Date
July 1 2010
Last Update
June 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan, 11217